HLS Therapeutics Inc. announced the appointment of Craig million as Chief Executive Officer ("CEO") of the Company, effective May 1, 2023, concurrent with the retirement of Gilbert Godin. Mr. Godin will remain CEO until that date and will assist with the transition. Mr. Godin will retire from the Board of Directors and Mr. million will be appointed to the Board on May 1, 2023.

Mr. million was selected after an extensive search conducted by the HLS Board. Mr. Millian's significant experience successfully commercializing new products and managing large business units in the specialty pharmaceutical industry makes him the ideal candidate to lead HLS. Mr. million most recently served as Chief Operating Officer at Corbus Pharmaceuticals where, following a major corporate development, he helped lead an organizational transformation into a precision oncology company that has in- licensed multiple promising assets.

Prior to Corbus, Mr. million held various commercial leadership positions at EMD Serono, where he was responsible for leading the strategic direction and driving operating results for several important franchises in the U.S. Previously, Mr. million served as Vice President, Commercial at Vertex Pharmaceuticals, where he helped design and build commercial infrastructure, organizational capabilities, and go-to-market plans in advance of their first commercial launch. Earlier in his career, Mr. million held marketing leadership roles for several blockbuster brands at both Pfizer Inc. and Sanofi. Mr. million holds an MBA from New York University and a BS degree in Finance from the University of Pennsylvania.